News
Eli Lilly's LLY -0.28% Get Free Report short percent of float has fallen 3.96% since its last report. The company recently reported that it has 7.71 million shares sold short, which is 0.97% of all ...
5d
Zacks.com on MSNEli Lilly (LLY) Dips More Than Broader Market: What You Should KnowIn the most recent trading session, Eli Lilly (LLY) closed at $771.75, indicating a -3.45% shift from the previous trading day.
Finally, don't discount legal challenges to the president's tariffs. An argument could be made that pharmaceutical products ...
Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.
On June 23, Eli Lilly and Company (NYSE:LLY) declared a quarterly dividend of $1.50 per share, which was in line with its ...
2d
Zacks.com on MSNBrokers Suggest Investing in Lilly (LLY): Read This Before Placing a BetThe average brokerage recommendation (ABR) for Lilly (LLY) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after ...
6d
Zacks Investment Research on MSNInvestors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to KnowEli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...
2d
MoneySense on MSNSingle-stock ETFs: Approach with cautionWhether for income or day trading, these ETFs are more complex and potentially risky products than they first appear. Buyer ...
The economy is struggling between maintaining stable prices and ensuring high employment. The Federal Reserve is under ...
5d
MarketBeat on MSNGoldman Spotlights These 3 Stocks in Its Bullish S&P 500 OutlookDetailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Eli Lilly’s stock closed at $771.75, slipping 3.45% and lagging the broader market. The company’s shares fell despite ...
2d
Stockhead on MSNScoPo’s Powerplays: CSL leads a 5pc ASX health stocks rallyThe sale represents Clever Culture’s fifth engagement with a leading pharma manufacturer, including AstraZeneca, Bristol Myers Squibb and Thermo Fisher. The company is due to report its Q4 FY25 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results